Ezetimibe improves postprandial hyperlipemia and its induced endothelial dysfunction

Kei Yunoki, Kazufumi Nakamura, Toru Miyoshi, Kenki Enko, Kunihisa Kohno, Hiroshi Morita, Kengo F. Kusano, Hiroshi Itoh

Research output: Contribution to journalArticle

49 Citations (Scopus)

Abstract

Objective: Postprandial hyperlipemia has been shown to impair endothelial function and contribute to the development of atherosclerosis. We investigated the association between postprandial lipid profiles and endothelial function, and we examined the effects of ezetimibe on postprandial hyperlipemia and lipemia-induced endothelial dysfunction. Methods: A randomized prospective trial in which 10. mg/day of ezetimibe was administered to 10 subjects for 4 weeks and not administered to 10 subjects (control group) was performed. Lipid profiles and endothelial function, assessed by brachial artery flow-mediated dilation (FMD) during a fasting state and at 2, 4, 6 and 8. h after an oral cookie loading test, were determined before and after treatment for 4 weeks. Results: In all subjects before treatment, the maximum reduction in postprandial %FMD was significantly correlated with the maximum increases in postprandial triglyceride (TG) (r = -0.499, P<0.05) and apolipoprotein B-48 (apoB-48) concentrations (r = -0.551, P<0.05). Ezetimibe treatment for 4 weeks significantly suppressed postprandial elevation in TG (area under the incremental curve, from 1419 ± 594 to 968 ± 321. mg. h/dl, P<0.05), remnant lipoprotein cholesterol (from 66.9 ± 27.6 to 38.9 ± 15.4. mg. h/dl, P<0.01) and apoB-48 (from 58.8 ± 27.5 to 36.2 ± 17.0 μg. h/ml, P<0.05) concentrations, and postprandial endothelial dysfunction assessed by %FMD (maximum reduction in %FMD, from -2.6 ± 1.1% to -1.2 ± 0.8%, P<0.05), whereas no significant changes were observed in the control group. Conclusion: Postprandial hyperlipemia is closely correlated with transient endothelial dysfunction. Ezetimibe improves postprandial hyperlipemia and its induced endothelial dysfunction.

Original languageEnglish
Pages (from-to)486-491
Number of pages6
JournalAtherosclerosis
Volume217
Issue number2
DOIs
Publication statusPublished - Aug 2011

Fingerprint

Hyperlipidemias
Dilatation
Apolipoprotein B-48
Triglycerides
Lipids
Control Groups
Brachial Artery
Area Under Curve
Fasting
Atherosclerosis
Ezetimibe

Keywords

  • Endothelial function
  • Ezetimibe
  • Postprandial hyperlipemia
  • Triglyceride-rich lipoproteins

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Ezetimibe improves postprandial hyperlipemia and its induced endothelial dysfunction. / Yunoki, Kei; Nakamura, Kazufumi; Miyoshi, Toru; Enko, Kenki; Kohno, Kunihisa; Morita, Hiroshi; Kusano, Kengo F.; Itoh, Hiroshi.

In: Atherosclerosis, Vol. 217, No. 2, 08.2011, p. 486-491.

Research output: Contribution to journalArticle

@article{c504abf29bb8472ca4698e783ae7c861,
title = "Ezetimibe improves postprandial hyperlipemia and its induced endothelial dysfunction",
abstract = "Objective: Postprandial hyperlipemia has been shown to impair endothelial function and contribute to the development of atherosclerosis. We investigated the association between postprandial lipid profiles and endothelial function, and we examined the effects of ezetimibe on postprandial hyperlipemia and lipemia-induced endothelial dysfunction. Methods: A randomized prospective trial in which 10. mg/day of ezetimibe was administered to 10 subjects for 4 weeks and not administered to 10 subjects (control group) was performed. Lipid profiles and endothelial function, assessed by brachial artery flow-mediated dilation (FMD) during a fasting state and at 2, 4, 6 and 8. h after an oral cookie loading test, were determined before and after treatment for 4 weeks. Results: In all subjects before treatment, the maximum reduction in postprandial {\%}FMD was significantly correlated with the maximum increases in postprandial triglyceride (TG) (r = -0.499, P<0.05) and apolipoprotein B-48 (apoB-48) concentrations (r = -0.551, P<0.05). Ezetimibe treatment for 4 weeks significantly suppressed postprandial elevation in TG (area under the incremental curve, from 1419 ± 594 to 968 ± 321. mg. h/dl, P<0.05), remnant lipoprotein cholesterol (from 66.9 ± 27.6 to 38.9 ± 15.4. mg. h/dl, P<0.01) and apoB-48 (from 58.8 ± 27.5 to 36.2 ± 17.0 μg. h/ml, P<0.05) concentrations, and postprandial endothelial dysfunction assessed by {\%}FMD (maximum reduction in {\%}FMD, from -2.6 ± 1.1{\%} to -1.2 ± 0.8{\%}, P<0.05), whereas no significant changes were observed in the control group. Conclusion: Postprandial hyperlipemia is closely correlated with transient endothelial dysfunction. Ezetimibe improves postprandial hyperlipemia and its induced endothelial dysfunction.",
keywords = "Endothelial function, Ezetimibe, Postprandial hyperlipemia, Triglyceride-rich lipoproteins",
author = "Kei Yunoki and Kazufumi Nakamura and Toru Miyoshi and Kenki Enko and Kunihisa Kohno and Hiroshi Morita and Kusano, {Kengo F.} and Hiroshi Itoh",
year = "2011",
month = "8",
doi = "10.1016/j.atherosclerosis.2011.04.019",
language = "English",
volume = "217",
pages = "486--491",
journal = "Atherosclerosis",
issn = "0021-9150",
publisher = "Elsevier Ireland Ltd",
number = "2",

}

TY - JOUR

T1 - Ezetimibe improves postprandial hyperlipemia and its induced endothelial dysfunction

AU - Yunoki, Kei

AU - Nakamura, Kazufumi

AU - Miyoshi, Toru

AU - Enko, Kenki

AU - Kohno, Kunihisa

AU - Morita, Hiroshi

AU - Kusano, Kengo F.

AU - Itoh, Hiroshi

PY - 2011/8

Y1 - 2011/8

N2 - Objective: Postprandial hyperlipemia has been shown to impair endothelial function and contribute to the development of atherosclerosis. We investigated the association between postprandial lipid profiles and endothelial function, and we examined the effects of ezetimibe on postprandial hyperlipemia and lipemia-induced endothelial dysfunction. Methods: A randomized prospective trial in which 10. mg/day of ezetimibe was administered to 10 subjects for 4 weeks and not administered to 10 subjects (control group) was performed. Lipid profiles and endothelial function, assessed by brachial artery flow-mediated dilation (FMD) during a fasting state and at 2, 4, 6 and 8. h after an oral cookie loading test, were determined before and after treatment for 4 weeks. Results: In all subjects before treatment, the maximum reduction in postprandial %FMD was significantly correlated with the maximum increases in postprandial triglyceride (TG) (r = -0.499, P<0.05) and apolipoprotein B-48 (apoB-48) concentrations (r = -0.551, P<0.05). Ezetimibe treatment for 4 weeks significantly suppressed postprandial elevation in TG (area under the incremental curve, from 1419 ± 594 to 968 ± 321. mg. h/dl, P<0.05), remnant lipoprotein cholesterol (from 66.9 ± 27.6 to 38.9 ± 15.4. mg. h/dl, P<0.01) and apoB-48 (from 58.8 ± 27.5 to 36.2 ± 17.0 μg. h/ml, P<0.05) concentrations, and postprandial endothelial dysfunction assessed by %FMD (maximum reduction in %FMD, from -2.6 ± 1.1% to -1.2 ± 0.8%, P<0.05), whereas no significant changes were observed in the control group. Conclusion: Postprandial hyperlipemia is closely correlated with transient endothelial dysfunction. Ezetimibe improves postprandial hyperlipemia and its induced endothelial dysfunction.

AB - Objective: Postprandial hyperlipemia has been shown to impair endothelial function and contribute to the development of atherosclerosis. We investigated the association between postprandial lipid profiles and endothelial function, and we examined the effects of ezetimibe on postprandial hyperlipemia and lipemia-induced endothelial dysfunction. Methods: A randomized prospective trial in which 10. mg/day of ezetimibe was administered to 10 subjects for 4 weeks and not administered to 10 subjects (control group) was performed. Lipid profiles and endothelial function, assessed by brachial artery flow-mediated dilation (FMD) during a fasting state and at 2, 4, 6 and 8. h after an oral cookie loading test, were determined before and after treatment for 4 weeks. Results: In all subjects before treatment, the maximum reduction in postprandial %FMD was significantly correlated with the maximum increases in postprandial triglyceride (TG) (r = -0.499, P<0.05) and apolipoprotein B-48 (apoB-48) concentrations (r = -0.551, P<0.05). Ezetimibe treatment for 4 weeks significantly suppressed postprandial elevation in TG (area under the incremental curve, from 1419 ± 594 to 968 ± 321. mg. h/dl, P<0.05), remnant lipoprotein cholesterol (from 66.9 ± 27.6 to 38.9 ± 15.4. mg. h/dl, P<0.01) and apoB-48 (from 58.8 ± 27.5 to 36.2 ± 17.0 μg. h/ml, P<0.05) concentrations, and postprandial endothelial dysfunction assessed by %FMD (maximum reduction in %FMD, from -2.6 ± 1.1% to -1.2 ± 0.8%, P<0.05), whereas no significant changes were observed in the control group. Conclusion: Postprandial hyperlipemia is closely correlated with transient endothelial dysfunction. Ezetimibe improves postprandial hyperlipemia and its induced endothelial dysfunction.

KW - Endothelial function

KW - Ezetimibe

KW - Postprandial hyperlipemia

KW - Triglyceride-rich lipoproteins

UR - http://www.scopus.com/inward/record.url?scp=79960698721&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79960698721&partnerID=8YFLogxK

U2 - 10.1016/j.atherosclerosis.2011.04.019

DO - 10.1016/j.atherosclerosis.2011.04.019

M3 - Article

VL - 217

SP - 486

EP - 491

JO - Atherosclerosis

JF - Atherosclerosis

SN - 0021-9150

IS - 2

ER -